In Phase 1 and 2a clinical trials, once-daily subcutaneous injections of RG7697 (0.252.5 mg) for 14 days in 56 patients with T2DM and 1.8 mg of RG7697 for 12 weeks in patients with T2DM who were poorly responsive to metformin reduced body weight and improved glycemic control
These treatments can help reduce appetite, control cravings, and make it easier to stay in a calorie deficit
Studies are still happening to understand why. The data from Dandelion Health showed that the 10% of people with the best response to GLP-1s had results that mirrored what clinical trials found, but the 10% with the least success with the treatments had no weight change, or even an increase in weight, over time
Integrating the result from the CVOTs in their meta-analysis, Sattar and colleagues found that the GLP-1 RA drug class may reduce the risk of hospital admission for HF by 11% (HR vs
However, GLP-1 agonists slow gastric emptying, which can affect the absorption of oral medications taken around the same time
Beyond these immediate metabolic effects, GLP-1 also influences lipid metabolism, inflammation, and cardiovascular health, contributing to overall metabolic stability
